|
Type of economic evaluation
| | |
|
CEA
|
21
|
70
|
|
CUA
|
5
|
17
|
|
CBA
|
4
|
13
|
|
Study design
| | |
|
RCT
|
8
|
27
|
|
Quasi-experimental
|
3
|
10
|
|
Modelling
|
6
|
20
|
|
Observational (prospective, retrospective etc.)
|
13
|
43
|
|
Perspective evaluated
| | |
|
Societal
|
0
|
0
|
|
Government
|
3
|
10
|
|
Healthcare system/Healthcare provider
|
23
|
77
|
|
Third party
|
2
|
7
|
|
Patients
|
1
|
3
|
|
Mixed
|
1
|
3
|
|
Type of sensitivity analysis
| | |
|
One-way analysis
|
5
|
17
|
|
Multi-way analysis
|
1
|
3
|
|
Univariate/multivariate regression
|
1
|
3
|
|
Probabilistic analysis
|
1
|
3
|
|
Not performed
|
22
|
73
|
|
Time horizon
| | |
|
<= 1 year
|
8
|
27
|
|
1-10 years
|
5
|
17
|
|
Over 10 years
|
5
|
17
|
|
Not specified
|
12
|
40
|
|
Type of outcome
| | |
|
QALY/DALY
|
5
|
17
|
|
Intermediate (physiological, functional, etc.)
|
21
|
70
|
|
Monetary
|
4
|
13
|
|
Level of care and intervention type
| | |
|
Primary prevention
|
2
|
7
|
|
Curative (Surgical/Medical procedure)
|
10
|
33
|
|
Curative (Pharmaceuticals)
|
7
|
23
|
|
Diagnostic/screening (secondary prevention)
|
10
|
33
|
|
Mode of delivery of care
|
1
|
3
|
|
Type of data used
| | |
|
Primary data
|
22
|
73
|
|
Secondary data
|
4
|
13
|
|
Mixed
|
4
|
13
|
|
Type of costs included
| | |
|
Direct medical costs
|
30
|
100
|
|
Direct non-medical costs
|
4
|
13
|
|
Indirect costs (Productivity loss)
|
0
|
0
|
